Skip to content
Create account to build your panelHelp me choose

Hormone Changes in Your 20s, 30s, and 40s: What to Expect

By the EllaDx team · Updated November 5, 2026 · 15 min read

For education only, not a diagnosis. Talk to your clinician about your results.

Two women in sports tops seen from behind, side by side
← Back to Journal

Your hormones are not static. They can shift across your menstrual cycle and, most dramatically, across the decades of your life. Understanding what research shows about each decade can help you know when a change is worth raising with your clinician.

The Big Picture: Hormonal Trajectory Across a Woman's Life

Before diving into each decade, it helps to understand the general trajectory of key reproductive and metabolic hormones:

  • Estrogen: Can stay fairly steady through the reproductive years (Burger et al., 2007), then run higher and swing unpredictably in perimenopause (Prior, 2005). In a large US study, mean levels began to fall about 2 years before the final period (Randolph et al., 2011)
  • Progesterone: Luteal phase levels can fall with reproductive aging (Hale et al., 2007), and lower levels can occur in perimenopause even while cycles are regular (Prior, 2005)
  • Testosterone: Can decline steeply with age, and the decline can be greater in the earlier decades than the later ones (Davison et al., 2005)
  • DHEA-S: Can follow the same pattern, with the steepest decline in the earlier decades (Davison et al., 2005)
  • FSH (follicle-stimulating hormone): Can start to rise about 6 years before the final period (Randolph et al., 2011), while cycles are still regular (Hale et al., 2009)
  • AMH (anti-Mullerian hormone): Can peak at around age 24 to 25 and then decline up to menopause (Kelsey et al., 2011), as the number of ovarian follicles falls (Burger et al., 2007)
  • Thyroid hormones: Can shift at any age. Abnormal thyroid results can become more common with age, though a large study of Japanese women found no distinct change at menopause itself (Hayashi et al., 2026)

Your 20s: Hormonal Peak and Hidden Vulnerabilities

AMH can reach its peak in the mid-20s (Kelsey et al., 2011), and testosterone and DHEA-S can be at their highest in early adult life (Davison et al., 2005). But this decade is not without its challenges.

What May Be Normal in Your 20s

  • Regular menstrual cycles, which averaged about 29 days in a large study of app users (Bull et al., 2019)
  • Higher AMH, a marker of ovarian reserve, near its peak (Kelsey et al., 2011)
  • Testosterone and DHEA-S levels can be the highest of your adult life (Davison et al., 2005)

What to Watch For

  • PCOS onset: Features of polycystic ovary syndrome can begin early and change through the teens and adult life (Joham et al., 2022), with irregular periods and elevated androgens (Azziz et al., 2016). It can raise the risk of type 2 diabetes and heart problems (Azziz et al., 2016), so these symptoms are worth raising with a clinician.
  • Birth control masking: The pill is also used to treat irregular periods, acne and unwanted hair in PCOS (Legro et al., 2013), so those signs can be less noticeable while you take it. It can also lower testosterone and raise SHBG (Zimmerman et al., 2014), which can change how hormone results read.
  • Hypothalamic amenorrhea: A loss of periods that can happen with stress, weight loss, excessive exercise, or a mix of these (Gordon et al., 2017). It can lead to bone loss and infertility, so missed periods are worth a visit.
  • Thyroid dysfunction: Hashimoto's thyroiditis is the most common cause of primary hypothyroidism in places with enough iodine (Duntas et al., 2026), and it affects about four times as many women as men (Hu et al., 2022).

Testing in Your 20s

Testing can be most useful when there's a question to answer. For adults without symptoms, the US Preventive Services Task Force found too little evidence to judge routine thyroid screening (LeFevre et al., 2015). If you have symptoms, a clinician may consider:

  • Thyroid panel (TSH, Free T4, Free T3, TPO antibodies), if you have symptoms of a thyroid problem
  • Androgens (total and free testosterone), if you have irregular periods or signs of PCOS (Bizuneh et al., 2025)
  • Metabolic markers (glucose, HbA1c), if you have PCOS (Goodman et al., 2015)
  • Ferritin, if you have symptoms of iron deficiency or heavy periods (Auerbach et al., 2025)

Your clinician can help you decide what fits your situation. See what we test.

Your 30s: The Subtle Shift

In your 30s, cycles may still be regular while some hormones keep changing in the background. In a large study of app users, mean cycle length fell slightly each year from age 25 to 45 (Bull et al., 2019).

What May Be Normal in Your 30s

  • Continued regular cycles for many women, though they can get slightly shorter (Bull et al., 2019)
  • Gradual decline in AMH (Kelsey et al., 2011) - but a lower AMH alone may not mean lower natural fertility (Steiner et al., 2017)
  • Testosterone and DHEA-S can continue their decline (Davison et al., 2005)

What to Watch For

  • Worsening PMS: Hormone fluctuations can trigger premenstrual symptoms, and severe PMS can disrupt daily life (Yonkers et al., 2008). If your symptoms are getting worse, track them against your cycle and talk to a clinician. Treatments are available (Yonkers et al., 2008).
  • Fertility challenges: In women aged 30 to 44 with no known infertility who had just started trying, low AMH or high FSH wasn't linked with lower chances of conceiving, and the authors didn't support these tests for judging natural fertility (Steiner et al., 2017). Ovarian reserve tests can predict egg yield in IVF, but they can be poor predictors of reproductive potential apart from age (ASRM Practice Committee, 2020). If you're having trouble conceiving, a clinician can run a fertility evaluation (ASRM Practice Committee, 2026).
  • Postpartum hormone disruption: Postpartum thyroiditis affects about 5% of women in the first year after giving birth (Nguyen et al., 2019). It can cause fatigue, dry skin and memory problems (Stagnaro-Green, 2012). Low mood after birth needs prompt care, whatever your labs show.
  • New onset anxiety or mood changes: Talk to a clinician, and don't wait on lab tests to get help. The US Preventive Services Task Force recommends screening adults for anxiety disorders (Barry et al., 2023).

Testing in Your 30s

  • Everything from the 20s list, if you have those symptoms, plus:
  • Diabetes screening: Recommended from age 35 to 70 for adults with overweight or obesity (Davidson et al., 2021)
  • Progesterone, as part of a fertility workup or if cycles are irregular. It needs timing to your own cycle, because ovulation day can vary a lot (Bull et al., 2019)
  • AMH, if you're planning IVF or a clinician has a specific question. Research doesn't support using it to judge your chances of natural conception (Steiner et al., 2017)
  • Inflammatory markers: The US Preventive Services Task Force found the evidence insufficient to add hsCRP to heart risk assessment in adults without symptoms (Curry et al., 2018)

Ask your clinician which of these fit your plans and symptoms. See what we test.

Your 40s: The Perimenopausal Transition

The 40s can bring big hormonal shifts. The menopausal transition can begin in the mid-40s (Burger et al., 2007), and perimenopausal changes can start as early as age 35 (Prior, 2005). In a large US study, the median length of the transition ranged from about 4 to about 9 years, and it was longer in women who started younger (Paramsothy et al., 2017). This phase can be characterized by hormonal instability rather than simple decline (Burger et al., 2007).

What May Be Normal in Your 40s

  • Cycle changes: Periods may become shorter, longer, heavier, lighter, or irregular. Bleeding changes are how the transition is staged (Harlow et al., 2012)
  • Estrogen fluctuation: Counterintuitively, estradiol can run higher in perimenopause (Prior, 2005) before declining later on (Randolph et al., 2011). Symptoms can come from either high or low levels (Burger, 2011)
  • Progesterone decline: Cycles without ovulation can become more frequent, making up 40% to 60% of cycles in the late transition (Burger, 2011), and luteal progesterone can fall (Hale et al., 2007)
  • FSH can rise: As inhibin B falls, FSH can climb (Burger et al., 2007)
  • Testosterone can continue declining with age, though natural menopause itself showed no independent effect (Davison et al., 2005)

What to Watch For

  • Vasomotor symptoms: About 50% to 75% of women can have hot flashes or night sweats during the transition (Crandall et al., 2023), and hot flashes can be moderately to severely bothersome for about one-third of women (Santoro, 2016)
  • Sleep disruption: Trouble falling and staying asleep can increase through the transition, and more frequent hot flashes were linked with worse sleep (Kravitz et al., 2008)
  • Mood changes: Depressive symptoms can increase during the transition (Freeman et al., 2004), and anxiety can too (Santoro, 2016). Most midlife women who have major depression have had an earlier episode (Maki et al., 2018), but a first episode can happen (Bromberger et al., 2009). See a clinician about low mood or anxiety, and don't wait on lab results. If you have thoughts of harming yourself, call or text 988.
  • Cognitive changes: In a large US study, perimenopause was linked with a dip in learning and memory that improved after menopause (Greendale et al., 2009)
  • Weight redistribution: Fat gain can speed up and lean mass can fall at the start of the transition, even though the pace of weight gain may not change (Greendale et al., 2019)
  • Heavy bleeding: In a large US study, about one-third of women reported at least three episodes of heavy bleeding lasting 3 or more days, and fibroids were one factor linked with it (Paramsothy et al., 2014). See a clinician about heavy, prolonged or unusual bleeding, and get urgent care if you feel faint.
  • Bone density changes: Bone loss can begin about a year before the final period and can be fastest through 2 years after it (Greendale et al., 2012)

Testing in Your 40s

A hormone panel can't pin down perimenopause. Staging relies on bleeding patterns (Harlow et al., 2012), and FSH and estradiol vary so unpredictably that they have little diagnostic value during the transition (Burger, 2011). A clinician may still consider:

  • Thyroid panel, if you have symptoms - abnormal results can become more common with age (Hayashi et al., 2026)
  • Lipid panel, glucose and HbA1c - cardiovascular risk can accelerate during the transition (El Khoudary et al., 2020), and diabetes screening is recommended for adults aged 35 to 70 with overweight or obesity (Davidson et al., 2021)
  • Ferritin, if you have heavy periods or symptoms of iron deficiency (Auerbach et al., 2025)
  • Bone health: Osteoporosis screening is recommended from age 65, or sooner after menopause if you're at increased risk (Nicholson et al., 2025)

Your clinician can help you decide what fits your symptoms and risks. See what we test.

A Practical Approach to Testing

You don't need to wait for symptoms to become unbearable before talking to a clinician. But we found no guideline that recommends regular hormone testing for people who feel well:

  • 20s: Test when there's a reason, such as irregular periods or signs of PCOS.
  • 30s: Follow standard screening, and test for symptoms or if you're having trouble conceiving.
  • 40s: Let symptoms guide perimenopause care, alongside standard heart, diabetes and bone screening.

A single hormone result is only a snapshot. Hormones can move across the cycle and shift unpredictably in the transition (Burger, 2011). Bring your symptoms, your cycle history and your questions to your clinician. That context can matter as much as any one number.

References

  • Santoro, N. (2016). Perimenopause: from research to practice. Journal of Women's Health, 25(4), 332-339. PMID 26653408
  • Harlow, S. D., et al. (2012). Executive summary of the Stages of Reproductive Aging Workshop + 10. Journal of Clinical Endocrinology & Metabolism, 97(4), 1159-1168. PMID 22344196
  • Prior, J. C. (2005). Ovarian aging and the perimenopausal transition. Endocrine, 26(3), 297-300. PMID 16034185
  • Freeman, E. W., et al. (2004). Hormones and menopausal status as predictors of depression in women in transition to menopause. Archives of General Psychiatry, 61(1), 62-70. PMID 14706945
  • Davison, S. L., et al. (2005). Androgen levels in adult females: changes with age, menopause, and oophorectomy. Journal of Clinical Endocrinology & Metabolism, 90(7), 3847-3853. PMID 15827095
  • Burger, H. G., et al. (2007). A review of hormonal changes during the menopausal transition: focus on findings from the Melbourne Women's Midlife Health Project. Human Reproduction Update, 13(6), 559-565. PMID 17630397
  • Randolph, J. F., et al. (2011). Change in follicle-stimulating hormone and estradiol across the menopausal transition: effect of age at the final menstrual period. Journal of Clinical Endocrinology & Metabolism, 96(3), 746-754. PMID 21159842
  • Hale, G. E., et al. (2007). Endocrine features of menstrual cycles in middle and late reproductive age and the menopausal transition classified according to the Staging of Reproductive Aging Workshop (STRAW) staging system. Journal of Clinical Endocrinology & Metabolism, 92(8), 3060-3067. PMID 17550960
  • Hale, G. E., et al. (2009). Hormonal changes and biomarkers in late reproductive age, menopausal transition and menopause. Best Practice & Research Clinical Obstetrics & Gynaecology, 23(1), 7-23. PMID 19046657
  • Kelsey, T. W., et al. (2011). A validated model of serum anti-müllerian hormone from conception to menopause. PLOS One, 6(7), e22024. PMID 21789206
  • Hayashi, S., et al. (2026). Menopausal Transition and Thyroid Function Trajectories: A Large-Scale Longitudinal Study of Healthy Women. Journal of Clinical Endocrinology & Metabolism, dgag337. PMID 42615120
  • Bull, J. R., et al. (2019). Real-world menstrual cycle characteristics of more than 600,000 menstrual cycles. NPJ Digital Medicine, 2, 83. PMID 31482137
  • Joham, A. E., et al. (2022). Polycystic ovary syndrome. Lancet Diabetes & Endocrinology, 10(9), 668-680. PMID 35934017
  • Azziz, R., et al. (2016). Polycystic ovary syndrome. Nature Reviews. Disease Primers, 2, 16057. PMID 27510637
  • Legro, R. S., et al. (2013). Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 98(12), 4565-4592. PMID 24151290
  • Zimmerman, Y., et al. (2014). The effect of combined oral contraception on testosterone levels in healthy women: a systematic review and meta-analysis. Human Reproduction Update, 20(1), 76-105. PMID 24082040
  • Gordon, C. M., et al. (2017). Functional Hypothalamic Amenorrhea: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism, 102(5), 1413-1439. PMID 28368518
  • Duntas, L. H., et al. (2026). Hashimoto's thyroiditis: two decades on. Lancet Diabetes & Endocrinology, S2213-8587(26)00189-0. PMID 42843400
  • Hu, X., et al. (2022). Global prevalence and epidemiological trends of Hashimoto's thyroiditis in adults: A systematic review and meta-analysis. Frontiers in Public Health, 10, 1020709. PMID 36311599
  • LeFevre, M. L., et al. (2015). Screening for thyroid dysfunction: U.S. Preventive Services Task Force recommendation statement. Annals of Internal Medicine, 162(9), 641-650. PMID 25798805
  • Bizuneh, A. D., et al. (2025). Evaluating the diagnostic accuracy of androgen measurement in polycystic ovary syndrome: a systematic review and diagnostic meta-analysis to inform evidence-based guidelines. Human Reproduction Update, 31(1), 48-63. PMID 39305127
  • Goodman, N. F., et al. (2015). AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME - PART 2. Endocrine Practice, 21(12), 1415-1426. PMID 26642102
  • Auerbach, M., et al. (2025). Iron Deficiency in Adults: A Review. JAMA, 333(20), 1813-1823. PMID 40159291
  • Steiner, A. Z., et al. (2017). Association Between Biomarkers of Ovarian Reserve and Infertility Among Older Women of Reproductive Age. JAMA, 318(14), 1367-1376. PMID 29049585
  • Yonkers, K. A., et al. (2008). Premenstrual syndrome. Lancet, 371(9619), 1200-1210. PMID 18395582
  • Practice Committee of the American Society for Reproductive Medicine. (2020). Testing and interpreting measures of ovarian reserve: a committee opinion. Fertility and Sterility, 114(6), 1151-1157. PMID 33280722
  • Practice Committee of the American Society for Reproductive Medicine. (2026). Fertility evaluation of infertile women: a committee opinion. Fertility and Sterility, S0015-0282(26)01303-8. PMID 42901815
  • Nguyen, C. T., et al. (2019). Postpartum Thyroiditis. Clinical Obstetrics and Gynecology, 62(2), 359-364. PMID 30844908
  • Stagnaro-Green, A. (2012). Approach to the patient with postpartum thyroiditis. Journal of Clinical Endocrinology & Metabolism, 97(2), 334-342. PMID 22312089
  • Barry, M. J., et al. (2023). Screening for Anxiety Disorders in Adults: US Preventive Services Task Force Recommendation Statement. JAMA, 329(24), 2163-2170. PMID 37338866
  • Davidson, K. W., et al. (2021). Screening for Prediabetes and Type 2 Diabetes: US Preventive Services Task Force Recommendation Statement. JAMA, 326(8), 736-743. PMID 34427594
  • Curry, S. J., et al. (2018). Risk Assessment for Cardiovascular Disease With Nontraditional Risk Factors: US Preventive Services Task Force Recommendation Statement. JAMA, 320(3), 272-280. PMID 29998297
  • Paramsothy, P., et al. (2017). Duration of the menopausal transition is longer in women with young age at onset: the multiethnic Study of Women's Health Across the Nation. Menopause, 24(2), 142-149. PMID 27676632
  • Paramsothy, P., et al. (2014). Bleeding patterns during the menopausal transition in the multi-ethnic Study of Women's Health Across the Nation (SWAN): a prospective cohort study. BJOG, 121(12), 1564-1573. PMID 24735184
  • Burger, H. G. (2011). Unpredictable endocrinology of the menopause transition: clinical, diagnostic and management implications. Menopause International, 17(4), 153-154. PMID 22120939
  • Crandall, C. J., et al. (2023). Management of Menopausal Symptoms: A Review. JAMA, 329(5), 405-420. PMID 36749328
  • Kravitz, H. M., et al. (2008). Sleep disturbance during the menopausal transition in a multi-ethnic community sample of women. Sleep, 31(7), 979-990. PMID 18652093
  • Maki, P. M., et al. (2018). Guidelines for the evaluation and treatment of perimenopausal depression: summary and recommendations. Menopause, 25(10), 1069-1085. PMID 30179986
  • Bromberger, J. T., et al. (2009). Predictors of first lifetime episodes of major depression in midlife women. Psychological Medicine, 39(1), 55-64. PMID 18377672
  • Greendale, G. A., et al. (2009). Effects of the menopause transition and hormone use on cognitive performance in midlife women. Neurology, 72(21), 1850-1857. PMID 19470968
  • Greendale, G. A., et al. (2019). Changes in body composition and weight during the menopause transition. JCI Insight, 4(5), e124865. PMID 30843880
  • Greendale, G. A., et al. (2012). Bone mineral density loss in relation to the final menstrual period in a multiethnic cohort: results from the Study of Women's Health Across the Nation (SWAN). Journal of Bone and Mineral Research, 27(1), 111-118. PMID 21976317
  • El Khoudary, S. R., et al. (2020). Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association. Circulation, 142(25), e506-e532. PMID 33251828
  • Nicholson, W. K., et al. (2025). Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation Statement. JAMA, 333(6), 498-508. PMID 39808425